One of the more complex decisions in the cancer screening decision-making algorithm centers on the risk-benefit ratio. For patients in the screening pools, CT-based screening for lung and colon cancer meets the mark.

RadNet Inc. (Nasdaq:RDNT), a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services through a network of 248 subsidiary-owned and/or operated outpatient imaging centers, announced its participation in a clinical trial to evaluate the biomarker effects of the investigational drug E2609, a BACE inhibitor, which is being developed for the potential disease modifying treatment of Alzheimer's disease (AD).

Today, the U.S. Centers for Disease Control and Prevention (CDC) and the Alzheimer's Association® unveiled The Healthy Brain Initiative: The Public Health Road Map for State and National Partnerships, 2013-2018 at the 2013 Alzheimer's Association International Conference (AAIC® 2013) in Boston.

Given Imaging Ltd, (Nasdaq:GIVN), a world leader in gastrointestinal medical devices and pioneer of capsule endoscopy, today announced that PillCam(R) COLON has been cleared by Japan's Pharmaceuticals & Medical Devices Agency (PMDA) for diagnosis of colonic disease when colonoscopy is required but difficult to conduct, including patients unwilling or unable to undergo colonoscopy.

Evaluation of adrenal nodules with F-18 FDG PET/CT was given a mean score of 93 percent diagnostic accuracy with an almost equally high percentage of interreader agreement, suggesting subjective visual interpretation is an effective method of evaluation, according to a review published in the August issue of Academic Radiology.

Pediatric inflammatory bowel disease (IBD) patients have undergone an increasing number of diagnostic exams over the past decade, though cumulative lifetime estimated effective radiation doses remain relatively low, according to a study published in the July issue of the American Journal of Roentgenology.

Adjuvant chemotherapy may not be the best option for patients with certain subtypes of breast cancer who show no clear benefit, according to an extensive retrospective of four clinical trials published June 12 in Breast Cancer Research and Treatment.

Radioimmunotherapy with Lu-177 DOTA-rituximab represents a novel and well-matched treatment for B-cell Lymphoma, but no consensus on standardized dosimetry was available, until now, according to research published in the July issue of Journal of Nuclear Medicine.